Notable

Our predictive medicine platform employs advanced technology, including flow cytometry and robotic automation, to bio-simulate treatment of each patient’s cancer at the cellular level. Our biological response database provides improved insight into patient response, helping us to identify promising drugs to develop into new therapeutics. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation

Getting the right treatment to the right patient, the first time, is critical for people fighting cancer. By combining existing de-risked drugs with a proprietary predicted responder diagnostic, we're working to ensure that a patient will only receive treatment that is likely to work for them. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #drugdevelopment, #hematology, #hematologists, #bloodcancer, #leukemia, #MDS, #cancerresearch

Getting the right treatment to the right patient, the first time, is critical for people fighting cancer. By combining existing de-risked drugs with a proprietary predicted responder diagnostic, we're working to ensure that a patient will only receive treatment that is likely to work for them. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #drugdevelopment, #hematology, #hematologists, #bloodcancer, #leukemia, #MDS, #cancerresearch

Our mission at Notable is to develop therapeutics that work predictably for people fighting cancer. We are dedicated to developing novel therapeutics so that physicians will know whether a patient is likely to benefit before they recommend a treatment. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #drugdevelopment, #hematology, #hematologists, #bloodcancer, #leukemia, #MDS, #cancerresearch

It can take months to determine who will respond to a specific cancer treatment. This is time that many patients and their families simply cannot afford.   Acute myeloid leukemia is a deadly disease and as few as 15% of patients fighting relapsed/refractory AML respond to the current standard of care.    Notable #CSO Joseph Wagner shares his thoughts about unmet medical needs for patients fighting cancer. #AcuteMyeloidLeukemia #AML #cancer

ICYMI, Notable Labs poster, “Retrospective prediction of clinical response to standard-of-care therapies in acute myeloid leukemia by an ex vivo drug sensitivity assay using cryopreserved primary samples,” presented at the American Association for Cancer Research (AACR) 2024 in San Diego, CA (Abstract 2548). Kudos to Lokesh Patil, Notable Labs Platform Lead, who served as the lead author and poster presenter, as well as Oregon Health & Science University abstract co-authors Nicola Long and Cristina Tognon, PhD. These data suggest Ex vivo drug sensitivity assay using cryopreserved patient samples in the PPMP assay can predict clinical response. Please visit https://lnkd.in/ek4ztm7D. #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS

Check out Notable Labs poster, “Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for venetoclax-HMA relapsed/refractory acute myeloid leukemia patients,” presented last week at the American Association for Cancer Research (AACR) 2024 in San Diego, CA (Abstract 5178). Congratulations to Markus Lacher, Notable Labs VP of R&D who served as the lead author and poster presenter. These data suggest a strong correlation between volasertib resistant fractions treated with 31.6 and 100 nM of volasertib and AUCs, which could represent a suitable metric to stratify patients into responders and non-responders. These preliminary metrics predict that 32-33% of de novo patients and 25% of R/R AML patients would be predicted to be responders if they were treated with volasertib. Please visit https://lnkd.in/ex6Wk3kV Stanford Department of Medicine #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS #Volasertib

Notable Labs will present the following two posters at the American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024, in San Diego, CA: 1. Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for venetoclax-HMA relapsed/refractory acute myeloid leukemia patients (poster section 45, poster #19, abstract #5178). Session Date and Time: Tuesday April 9, 2024, 9:00 AM - 12:30 PM (PT) 2. Retrospective prediction of clinical response to standard-of-care therapies in acute myeloid leukemia by an ex vivo drug sensitivity assay using cryopreserved primary samples (poster section 45, poster #8, abstract #2548). Session Date and Time: Monday April 8, 2024, 9:00 AM - 12:30 PM (PT) Markus Lacher; Stanford Department of Medicine; Lokesh Patil; Nicola Long; Cristina Tognon #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS

Learn how Notable Labs is pioneering the integration of artificial intelligence (AI) into predictive precision medicine in this informative California Life Sciences (CLS) article, written by Chris Leonardi, Head of Clinical Alliances and Partnerships.  Chris explores how predictive precision outcomes compare to traditional methods, as was showcased at the 2023 American Association for Cancer Research (AACR) annual meeting. He also describes how AI’s ability to navigate complex datasets without prior knowledge of a drug’s specific cellular biology contributes to a comprehensive understanding of drug efficacy. Read more at https://lnkd.in/eBxUNsBz #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS #AcuteMyeloidLeukemia #artificialintelligence #AI #drugefficacy

Notable Labs Predictive Precision Medicine Platform (PPMP) uses AI and machine learning to provide a predictive score for a patient's likelihood to respond to a particular cancer treatment. NOTABLE’s PPMP is designed to identify and select clinically responsive patients prior to their treatment while also expediting clinical development in this patient population. NOTABLE is revolutionizing the way patients seek and receive treatment. Questions? Let’s talk: [email protected]. Learn more at notablelabs.com.   #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS